Abstract
IGF-II is a regulatory peptide which appears to be involved significantly in the progression of many tumors, while minimally involved in post-fetal non-tumor tissue. Interruption of IGF-II pathways therefore offers the possibility of tumor control with a high therapeutic index. Investigators should continue to evaluate tumors for the involvement of IGF-II as well as investigate clinically relevant means of disrupting those pathways.
Original language | English (US) |
---|---|
Pages (from-to) | 367-372 |
Number of pages | 6 |
Journal | Journal of Endocrinology |
Volume | 149 |
Issue number | 3 |
DOIs | |
State | Published - 1996 |
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Endocrinology